Clinical Trial Update: Bendamustine Combined With Rituximab for Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial evaluating the combination of bendamustine and rituximab for relapsed or refractory diffuse large B-cell lymphoma has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Diffuse Large B-cell Lymphoma

Drugs mentioned

• Bendamustine (Bendamustine)
• Rituximab (rituximab)

Snippet

Sponsor: Pharmatech | Conditions: Diffuse Large B-Cell Lymphoma | Phase 2 | Status: COMPLETED